Cel
Despite dramatic advances in molecular and imaging technologies, there are currently no effective pharmacological treatments for the core symptoms of autism spectrum disorder (ASD). Major obstructions to this include a lack of aetiologically-driven or pathophysiologically-accurate animal models; an absence of tests that indicate efficacy; and reliance of clinical trials on DSM/ICD10 categories which provide a collection of biologically heterogeneous patients. Further, even if novel treatments are developed there is no EU platform to clinically test them. Our hypothesis is that a focus on cross-species endophenotypes, finding biologically-homogenous groups of patients, and developing a clinical research network will overcome the limitations in target identification, early triage and clinical trials. Hence, leading European institutions and three SMEs will partner with the EFPIA to: a) develop in vitro models, and animal models that carry confirmed genetic risks, and in these animals to focus on cross-species endophenotypes (e.g. cognitive function, electrophysiology) to facilitate new drug discovery; b) validate the use of sMRI and fMRI-based endophenotypes in genetically-selected healthy volunteers, infants at risk for ASD, and children and adults (including twins) with and without ASD, as early and surrogate markers for efficacy; and to combine this with PET approaches to provide guidance regarding optimal clinical trial design; and c) identify biomarkers that can be used to stratify patients within an umbrella DSM-diagnosis, thus allowing for targeted clinical trials, individualized treatment and back-translation of subgroup-specific biomarkers into preclinical drug discovery. To increase the chance of a breakthrough we will implement new analytical approaches (e.g. support vector machine learning algorithms) and will actively collaborate with patient groups and other international efforts (e.g. the Autism Genetic Resource Exchange (AGRE)).
Dziedzina nauki
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesneurobiologycognitive neuroscience
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
Zaproszenie do składania wniosków
IMI-JU-03-2010
Zobacz inne projekty w ramach tego zaproszenia
System finansowania
JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)Koordynator
4070 Basel
Szwajcaria
Zobacz na mapie
Uczestnicy (26)
WC2R 2LS London
Zobacz na mapie
68159 Mannheim
Zobacz na mapie
6525 XZ Nijmegen
Zobacz na mapie
CB2 1TN Cambridge
Zobacz na mapie
Zakończenie uczestnictwa
101 Reykjavik
Zobacz na mapie
3584 CX Utrecht
Zobacz na mapie
4051 Basel
Zobacz na mapie
75724 Paris
Zobacz na mapie
Zakończenie uczestnictwa
80333 Muenchen
Zobacz na mapie
80539 Munchen
Zobacz na mapie
69117 Heidelberg
Zobacz na mapie
Zakończenie uczestnictwa
2750 Ballerup
Zobacz na mapie
17177 Stockholm
Zobacz na mapie
RG21 4FA Basingstoke
Zobacz na mapie
2340 Beerse
Zobacz na mapie
91190 GIF-SUR-YVETTE
Zobacz na mapie
1752 Villars-sur-Glâne
Zobacz na mapie
WC1E 7HX London
Zobacz na mapie
00128 Roma
Zobacz na mapie
08540 Princeton Nj
Zobacz na mapie
CT13 9NJ Sandwich
Zobacz na mapie
75015 PARIS 15
Zobacz na mapie
89081 Ulm
Zobacz na mapie
6709 PA Wageningen
Zobacz na mapie
101 Reykjavik
Zobacz na mapie
75008 Paris
Zobacz na mapie